[Treatment of severe hemoptysis with terlipressin. Study of the efficacy and tolerance of this product].
Terlipressin (Glypressin) is a "pro-hormone"; after intravenous injection the glycyl radicals are slowly cleaved by enzymatic action, liberating vasopressin. We have assessed the efficacy of terlipressin in the treatment of severe hemoptysis. The study was performed on 20 patients: in 5 cases there was very copious hemoptysis and in 15 cases there was repeated hemoptysis of lesser volume. The cause was distributed as follows: 6 cases of neoplasms, 5 were sequelae of tuberculosis, bronchial dilatation 2 cases, pneumonia with abscess 2 cases, chronic airflow obstruction (COPD) 2 cases and 3 cases of silicosis. The treatment consisted of a slow intravenous injection of 2 mgm 4 times per day (9 patients), then in 11 patients an injection of 2 mgm at the time of acute episodes followed by 1 mgm every 6 hours. The patients received an average of between 15 and 20 mgm of the product for a treatment lasting over 5 days at the maximum. The results were as follows: total success 12 cases; partial success (a reduction to at least one-third of the initial hemoptysis): 5 cases; failure: 3 cases. The failures were linked in two cases to neoplastic disease and in one case there was an intolerance to the drug which did not allow the treatment to be pursued.(ABSTRACT TRUNCATED AT 250 WORDS)
Ramon
P
P
Service de Pneumologie et Immuno-allergologie, Hôpital A.-Calmette, Lille.
Wallaert
B
B
Derollez
M
M
D'Odemont
J P
JP
Tonnel
A B
AB
D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006469:Hemoptysis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007275:Injections, Intravenous; D008236:Lypressin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077585:Terlipressin
D008236:Lypressin; D000077585:Terlipressin
Traitement des hémoptysies graves par la terlipressine. Etude de l'efficacité et de la tolérance du produit.